RxDoctor Payments Data

Adnan Yousaf, MD

Interventional Cardiology · Davenport, IANPI 1306324975

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 46.5% of the total. Reporting peaked in 2023 at $2,532 and has fallen 57.2% since, to $1,085 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.

$3,872in general payments, 2019–2025

Across 37 payments — averaging $104.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$985
  • Abbott$189
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$155
  • Kiniksa Pharmaceuticals, Ltd.$123
  • Abiomed$120
  • plus $501 from 7 others

What the payments were for

  • Grants$2948%
  • Travel & lodging$1,27633%
  • Food & beverage$1,97251%
  • Education$3309%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,872 in reported general payments places this provider in the 50th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$115,723
Medicare patients
687
Services billed
1,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$33,190
Metoprolol Succinate78$850
Rosuvastatin Calcium26$496
Atorvastatin Calcium42$346
Lisinopril41$261
Isosorbide Mononitrate ErIsosorbide Mononitrate29$250
ClopidogrelClopidogrel Bisulfate30$176
Carvedilol18$173
Losartan Potassium21$156
Furosemide47$152
Nitroglycerin19$141
Metoprolol Tartrate15$73
Amlodipine Besylate27$72
Warfarin Sodium12$40

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →